Performance & GH axis
ACE-031
Ramatercept, ActRIIB-Fc
ACE-031 is a soluble activin receptor type IIB fused to an antibody Fc fragment, developed by Acceleron for Duchenne muscular dystrophy. Its clinical trials were halted for safety and it was never approved.
Also known as: ramatercept, ActRIIB-Fc, ACE031, ACE 031
- Status
- ACE-031 is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Roughly 10 to 15 days, typical of an Fc-fusion protein.
- How it's taken
- Subcutaneous injection in the trial setting
- Mechanism
- Anabolic (IGF-1 / myostatin)
- Pathways
- Myostatin
How ACE-031 works
ACE-031 is a decoy receptor: the extracellular domain of ActRIIB fused to IgG1 Fc, which binds myostatin, activin A, GDF-11 and related ligands in circulation before they can reach cell-surface receptors. This is a ligand-trap approach, mechanistically distinct from bimagrumab, which blocks the receptor itself.
What research has looked at
- Phase 1 and 2 studies showed increases in lean mass and in serum markers consistent with effective myostatin pathway blockade.
- The decoy-receptor design captures multiple ligands simultaneously and had a half-life supporting infrequent dosing.
- It advanced further in Duchenne muscular dystrophy than most myostatin-pathway candidates.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Trials were discontinued after safety findings including epistaxis, telangiectasia and gum bleeding — consistent with off-target effects on vascular ligands in the TGF-beta family. This is the decisive fact about the compound.
- Development was terminated and no regulator has approved it. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- The bleeding signal illustrates a general problem with broad ligand traps: activin family members regulate vascular and haematopoietic processes well beyond muscle.
- Prohibited at all times under the WADA Prohibited List.
Sources
- PubMed research on ACE-031 ActRIIB-Fc Duchenne bleeding · NIH · National Library of Medicine
- DrugBank record for ramatercept · DrugBank
- Active clinical trials for ramatercept · U.S. National Library of Medicine
Track ACE-031 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
ACE-031 FAQ
What is ACE-031?
ACE-031 is a soluble activin receptor type IIB fused to an antibody Fc fragment, developed by Acceleron for Duchenne muscular dystrophy. Its clinical trials were halted for safety and it was never approved.
How does ACE-031 work?
ACE-031 is a decoy receptor: the extracellular domain of ActRIIB fused to IgG1 Fc, which binds myostatin, activin A, GDF-11 and related ligands in circulation before they can reach cell-surface receptors. This is a ligand-trap approach, mechanistically distinct from bimagrumab, which blocks the receptor itself.
Is ACE-031 FDA approved?
No. ACE-031 is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of ACE-031?
Reported half-life: Roughly 10 to 15 days, typical of an Fc-fusion protein.
How is ACE-031 taken?
Subcutaneous injection in the trial setting.
What side effects have been reported with ACE-031?
Reported in the sources: Trials were discontinued after safety findings including epistaxis, telangiectasia and gum bleeding — consistent with off-target effects on vascular ligands in the TGF-beta family. This is the decisive fact about the compound; Development was terminated and no regulator has approved it. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; The bleeding signal illustrates a general problem with broad ligand traps: activin family members regulate vascular and haematopoietic processes well beyond muscle; Prohibited at all times under the WADA Prohibited List.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.